Micromet and Nycomed Initiate Formal Preclinical Antibody Studies
Posted on: Wednesday, 25 June 2008, 12:03 CDT
Micromet and Nycomed have initiated formal preclinical safety studies for the anti-GM-CSF human antibody MT203. Micromet received $775,000 from Nycomed for the achievement of this milestone.
Under a 2007 agreement between the two companies, Micromet and Nycomed develop MT203, a fully human anti-GM-CSF antibody that may be useful for the treatment of various inflammatory and autoimmune diseases.
Preclinical studies support MT203's development for the treatment of rheumatoid arthritis and several other indications, including multiple sclerosis, psoriasis, asthma and chronic obstructive pulmonary disease.
Anders Ullman, executive vice president R&D at Nycomed, said: "Within our partnership, Micromet has continued to deliver encouraging data on MT203 related to the treatment of inflammatory and autoimmune diseases. MT203 represents an important asset in our early stage pipeline."
Source: Datamonitor
Related Articles
- Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
- Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
- Micromet and Nycomed Initiate Preclinical Safety Studies for Inflammatory Drug
- Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
- Micromet to Present at the Susquehanna Financial Group's SIGnificant Investment Options Conference on March 4, 2008
- Micromet to Present at Two Upcoming Investor Conferences
- TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial With TRC093 (D93), a Humanized Antibody for Cancer Treatment
- Micromet and Nycomed Enter Into Exclusive Worldwide Collaboration to Develop and Commercialize Anti-GM-CSF Antibodies for the Treatment of Inflammatory and Autoimmune Diseases
- Encouraging Data for Micromet's Novel Anti-Inflammatory
 |
 |
User Comments (0)
RSS Feeds